Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06072807 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2026 to Dec 2027v5
  2. Re-verified, no change to tracked fieldsv4
  3. Primary and study completion dates: Jul 2024 to Dec 2026
    • Start date changed from estimate of Dec 2023 to Dec 27, 2023
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2023 to Dec 2023
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months. Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.
Trial Details
NCT Number NCT06072807
Lead Sponsor Weill Medical College of Cornell University
Collaborators: GE Healthcare
Conditions
(from sponsor)		 Breast Cancer, Brain Metastases
Related terms Brain Neoplasms, Breast Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov